Elizabeth E Morgan
8 Papers
82 Citations
Elizabeth E Morgan is an academic researcher. The author has contributed to research in topics: Placebo & Cytokine. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE.
Halina Offner,Halina Offner,Alex Zamora,Heather Drought,Agata Matejuk,Agata Matejuk,Dominick L. Auci,Elizabeth E Morgan,Arthur A. Vandenbark,Arthur A. Vandenbark,Christopher L. Reading +10 more
TL;DR: Evaluating the suppressive effects of fluasterone (HE2500), a synthetic androstene derivative, and androstenetriol (HE2200), a natural androstane hormone on EAE suggests that HE2500 and/or HE2200 limit the production of autoimmune Th1 associated cytokines, and ultimately may be beneficial for patients with MS or other autoimmune diseases.
47
Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis
Elizabeth E Morgan,Christopher J. Nardo,Jocelyn P. Diveley,Joel Kunin,Richard M. Bartholomew,Ronald B. Moss,Dennis J. Carlo +6 more
TL;DR: It is demonstrated that immunization with TCR BV6S2/6S5 peptide vaccine in MS patients is safe and immunogenic, and supports a larger double-blind placebo controlled trial to determine the clinical efficacy of this approach.
21
A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse.
Halina Offner,Halina Offner,Alex Zamora,Sandhya Subramanian,Magdalena J. Polanczyk,Aric Krogstad,Dominick L. Auci,Elizabeth E Morgan,Christopher L. Reading +8 more
TL;DR: This is the first study to report that an IRH can ameliorate ongoing disease in a CIA mouse model with relevance to RA and to correlate that finding with decreases in pro-inflammatory cytokines.
14
•Journal Article
Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.
Dwight R. Stickney,Clarence N. Ahlem,Elizabeth E Morgan,Christopher L. Reading,Nanette Onizuka,James M. Frincke +5 more
TL;DR: The immune regulating DHEA metabolite, androst-5-ene-3β,7β,17β-triol (βAET), was evaluated for safety, cholesterol lowering, and vaccine enhancement in phase I and phase II clinical trials as discussed by the authors.
2
Original Article Phase I and Phase II clinical trials of androst-5-ene- 3β,7β,17β-triol
Dwight R. Stickney,Clarence N. Ahlem,Elizabeth E Morgan,Christopher L. Reading,Nanette Onizuka,James M. Frincke +5 more
- 01 Jan 2011
TL;DR: The utility of βAET in humans may be limited to maintenance of homeostasis in healthy adults and higher doses or chemical derivatives that are resistant to metabolic inactivation are likely necessary to treat human disease.
1